1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5): 1248–1259
2. du Bois A, Luck HJ, Meier W, Mobus V, Costa S, Richter B, Warm M, Bauknecht T, Schroder W, Ol-bricht S, Nitz U, Jackisch C. (1997) Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group.Semin Oncol (5 Suppl 15): S15–44–S15–52
3. Engel J, Schubert-Fritschle G (2001) Epidemiologie In Kuhn W (ed) Manual Maligne Ovarialtumoren. Tumorzentrum München, München S 1–9
4. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92(10): 2585–2591
5. Kuhn W, du Bois A, Pfisterer J (2001) Operative Therapie des fortgeschrittenen Ovarialkarzinoms. Gynäkologe 34:1050–1057